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framework for studying access to health care. ED visits were classified into avoid-
able or not using the New York University algorithm. Patient complexity was mea-
sured using the Chronic Illness Intensity Index (CI3), an index used to measure
need of case management intensity. We performed logistic regression models to
test for significant association between AEDV, and population at risk and health
care delivery characteristics. RESULTS: We found that 69% (179) of our population
had an ED visits during 2008-2009. Of these visits, 60% were classified as AEDV. The
analysis showed that women were 33% less likely to have an AEDV per month. Age
was negatively associated, with younger patients being more likely to have AEDV.
More complex patients were 6.6% more likely to have an AEDV. For every extra
physician a patient visited, the probability of having an AEDV per month increased
by 2.4%, however this was not significant (p 0.06) at 95% confidence interval.
CONCLUSIONS: Among high cost, high risk Medicaid patients there are certain
patient characteristics that can allow us to identify those at higher risk of having an
AEDV. This information could be use to identify groups that would benefit from
interventions to reduce ED utilization.
PHP55
A REVIEW OF THE NICE APPEALS PROCESS
Eaton JN1, Hawkins N2
1Oxford Outcomes Ltd, Oxford, Oxon, UK, 2Oxford Outcomes Ltd., Oxford, UK
OBJECTIVES: Formal systems of health technology appraisal (HTA) can directly
inform resource allocation in healthcare systems and have contributed to the eq-
uitable and efficient allocation of such resources. To engender and maintain sup-
port from a wide range of stakeholders it is important that HTA systems are seen a
socially just, particularly in the face of contentious decisions. Effective appeals
processes, internal or judicial, can have an important role in meeting this goal,
enabling stakeholders to directly question the evidence considered, its interpreta-
tion, and the decision making process. We conducted an empirical review of the
results of all appeals made to the National Institute for Clinical Excellence (NICE)
between the years 2000 and 2010, and consider whether NICE fulfills these
requirements.METHODS:A retrospective review of all completed NICE technology
appraisals published between March 2000 and October 2010 was conducted. Each
technology appraisal was investigated for appeals. Published appeals were then
categorized by appeal substance, stakeholder, and outcome. The results were pre-
sented as absolute numbers and proportions of overall responses. RESULTS: In this
study 29% of appraisals resulted in a published appeal of which 41% were upheld.
The most common ground for an appeal, 59% of total, was perversity of the deci-
sion, the main substance for those appeals was misinterpretation of the clinical or
cost-effectiveness evidence. By proportion of appeals upheld the most successful
appeal point was that the HTA did not meet the scope or was deemed to be ineq-
uitable. Appeals involving a professional body or patient group were also more
likely to be successful. CONCLUSIONS: Examination of appeals to NICE would sug-
gest that a socially just and effective appeals process is in place. Decisions are
reversible and transparent and stakeholders can both participate in and question
the decision process.
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OBJECTIVES: Over the last decade, specialist pharmacists across Europe have seen
an emergent role in many areas of the healthcare pathway. This research exam-
ined four key domains - clinical, policy, education and research - of influence of
specialist pharmacists with goal of understanding how they can impact market
access of drugs.METHODS: Structured interviews with 25 specialist oncology phar-
macists from EU5 exploring various aspects within the four identified domains of
influence. RESULTS: A selection of the most important roles of the specialist phar-
macist by domain is presented below: Clinical: 1) Coordinate safe and timely ad-
ministration of drugs and supportive treatment; 2) Coordinate outpatient support-
ive care focusing on management of symptoms; and 3) Help develop treatment
guidelines to ensure optimal use of supportive care medications. Policy: 1) Provide
formulary review for new drugs, and 2) Facilitate reimbursement for a more effi-
cient practice. Education: 1) Educate patients and members of the HC team about
drugs and their expected side effects and management, and 2) Educate members of
the public about prevention strategies and recommendation for screening and
early detection. Research: 1) Conduct internal treatment protocol audits to opti-
mise patient care pathway, and 2) Participate in institutional review board for
approval of clinical trials as well as scientific review and monitoring committees.
CONCLUSIONS: A cornerstone of market access is identification of important
stakeholders within a health care economy with the goal of understanding the
roles they play in the care pathway. The specialist pharmacist is an often over-
looked, but increasingly important stakeholder in the European health care sys-
tem. The multitude of roles played by the specialist pharmacist is in itself evidence
of increasing importance of the role. Pharmaceutical companies will need to en-
gage more closely with specialist pharmacists to ensure better patient outcomes
through appropriate use of drugs leading ultimately to increased market access.
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OBJECTIVES: The Committee for the Assessment of Hospital Drugs, led by the
Catalan Agency of Health Information Assessment and Quality, has provided evi-
dence-based information to regional health care decision-makers in Catalonia
about the added therapeutic value (ATV) of centralized approved drugs fit into the
orphan or advanced therapies category or have conditional approval or were ap-
proved in exceptional circumstances. This study describes the committee’s activity
since its creation.METHODS: Systematic reviews of efficacy, safety and cost-effec-
tiveness are conducted upon request from the Pharmacy Directorate and results
are appraised by expert panels. RESULTS: A total of 22 drugs (24 indications) for an
estimated population of 1.100 patients have been assessed. Most drugs were
granted approval for two major therapeutic areas: onco/hematological (41%) and
metabolic diseases (32%). Orphan designation had been given to 70% of all indica-
tions. Only 8 indications were given positive opinion based on 2 clinical trials. Most
pivotal studies were randomized phase III trials and were considered to have mod-
erate (63%) to high (25%) risk of bias. Placebo was the most frequent comparator in
controlled studies but was only considered appropriate in half. Primary endpoint
was a surrogate/intermediate endpoint in 94% of studies. Relevance of efficacy
results was difficult to interpret due to design flaws, small samples and short-term
follow-ups. Scarce or no data on effectiveness was available. Information on com-
parative safety was also scant and limited by short-term follow-ups. At time of
assessment cost-effectiveness data was missing in 66% of the indications. Re-
ported base-case incremental cost-effectiveness ratios from manufacturers ranged
from 16.000-565.000£/QALY. CONCLUSIONS: Defining ATV of new entities at the
time of introduction proved a challenge because of low quality studies and lack of
information about relative effectiveness. Registers and/or risk-sharing schemes
may be an alternative to gather more information new about drugs and establish
their real ATV while facilitating access.
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OBJECTIVES: Urban green spaces (UGS) are thought to impact on health and well-
being. Cost-effectiveness analysis (CEA) can help to determine if provision or in-
terventional use of urban green spaces can contribute to population health in a cost
effective manner. This mapping review aims to characterise the study designs,
independent variables, outcomes and outcome measures reported in the
literature. METHODS: Key health and medical databases were searched. Studies of
any design (except reviews) which attempted to value the health and wellbeing
effects of UGS were included. One reviewer selected studies with a proportion
checked by a second and third reviewer. Data were extracted from abstracts using
a standardised form. Data were coded using a grounded theory approach and syn-
thesised in graphical and tabular form. RESULTS: A total of 189 citations were
included. The most common study design was cross sectional regression analyses;
there were only three randomised controlled trials. Many putative independent
variables were identified, including psychological, socio-economic, environmental
and interventional variables. Settings and populations also varied. Outcomes
coded as health behaviours included physical activity, visit frequency, nutrition
and social interaction; those coded as health outcomes included general health,
mental health, quality of life, wellbeing, mortality, obesity and cardiovascular in-
dices amongst others. Outcome measures were generally not compatible with CEA.
Amongst 61 economic studies, the most common study type was hedonic pricing.
Only one limited CEA analysis was identified. CONCLUSIONS: Few randomised
studies have been performed and available evidence would not allow a traditional
CEA. Existing trials have limited external validity according to criteria normally
used in health contexts. Current evidence may better lend itself to logic modelling,
as the causal pathways are long and complex and green space is likely to act at both
the individual and population level. To aid CEA, future research should carefully
choose study design, outcomes and outcome measures.
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OBJECTIVES: We estimated increases in medical expenditures due to medication
nonadherence and potential savings of increasing adherence for members of a
prescription-drug benefit plan taking medications in four drug therapy classes
(TCs).METHODS:We used data from the Medical Expenditure Panel Survey (MEPS)
to estimate functional relationships between adherence and resource utilization
for patients taking medications in four TCs. Resource use included all-cause and
disease-specific annual hospitalizations and emergency room (ER) visits. TCs in-
cluded depression, diabetes, high blood cholesterol (cholesterol), and high blood
pressure or heart disease (heart). Adherence was estimated using the medication
possession ratio (MPR). MPR less than 80% was considered nonadherence. Average
medication expenditures, by TC, was obtained from a large prescription-drug da-
tabase. Expenditures per hospitalization and ER visit were estimated from MEPS.
Unit costs and functional relationships between adherence and resource use were
applied to estimate annual resource use and medication expenditure. Increased
expenditures due to nonadherence were estimated for nonadherent patients ver-
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